Targeted inhibition of complement using complement receptor 2-conjugated inhibitors attenuates EAE.

Area of Science:

• Neuroimmunology
• Autoimmune Diseases
• Complement System Biology

Background:

• Multiple sclerosis (MS) is a prevalent autoimmune demyelinating disease with limited therapeutic options for progressive forms.
• Current MS treatments primarily target relapsing forms and often have safety concerns or limited efficacy.
• A significant unmet need exists for effective therapies addressing both acute and chronic MS progression.

Purpose of the Study:

• To investigate the therapeutic potential of inhibiting complement activation in experimental autoimmune encephalomyelitis (EAE), an animal model for MS.
• To evaluate the efficacy of complement receptor 2 (CR2)-conjugated inhibitors in attenuating EAE.
• To determine if blocking the alternative complement pathway or C3 convertase impacts disease progression.

Main Methods:

• Utilized experimental autoimmune encephalomyelitis (EAE) mouse models.
• Administered CR2-Crry (inhibits all complement pathways at C3) and CR2-fH (inhibits the alternative pathway) prior to and during EAE onset.
• Assessed the impact of these inhibitors on acute and chronic EAE progression.

Main Results:

• Targeted inhibition of complement activation using CR2-conjugated inhibitors significantly attenuated EAE.
• Administration of CR2-Crry and CR2-fH effectively blocked the progression of both acute and chronic EAE.
• These findings demonstrate the protective effects of complement inhibition in a demyelinating disease model.

Conclusions:

• Inhibition of complement activation, particularly via the alternative pathway or C3 convertase, offers a promising therapeutic strategy for MS.
• CR2-conjugated inhibitors demonstrate potential for treating both acute and chronic forms of demyelinating diseases like MS.
• Targeting the complement system represents a viable approach to address unmet needs in multiple sclerosis treatment.